Clinical Trials Data Hemp THC 
Cannabis Law Report
JUNE 7, 2021
IGC”) (NYSE American: IGC) announces today that it has completed Cohort 2 of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease. This Phase 1 trial is currently testing IGC-AD1 for safety.
Cannabis Law Report
DECEMBER 2, 2021
(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The investigational new drug, IGC-AD1, is IGC’s proprietary Tetrahydrocannabinol (THC)-based candidate designed to treat certain symptoms of Alzheimer’s disease. The degree of the decrease varied by cohort.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
DECEMBER 14, 2021
(“IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. The trial was conducted as a multiple ascending dose (MAD) study.
The Cannigma
DECEMBER 14, 2021
This synthetic derivative of naturally occurring delta-9-Tetrahydrocannabinol (delta-9-THC) was first reported by noted cannabis chemist Professor Roger Adams at the University of Illinois in 1940. It was also later found that HHC can be produced in the lab during the conversion of THC to CBN in what is known as a disproportionation reaction.
Project CBD
AUGUST 6, 2019
Over 200 scientists from around the world attended the four-day conference, which included 65 oral presentations and nearly 200 posters covering a wide range of topics – with the caveat that researchers had to present new, unpiblished data. THC was present in 89 percent of the samples, but in most cases no amount of THC was provided.
Cannabis Law Report
AUGUST 29, 2019
It has been just over a month since the public comment period closed in the wake of the public hearing held by the FDA, “Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds”. THC by dry weight following the enactment of the 2018 Farm Bill. and its derivatives containing no more than 0.3%
Project CBD
AUGUST 6, 2019
Just over 500 participants from around the world attended the four-day conference, which included 65 oral presentations and nearly 200 posters covering a wide range of topics – with the caveat that researchers had to present new, unpublished data. THC was present in 89 percent of the samples, but in most cases no amount of THC was provided.
Expert insights. Personalized for you.
105 
Let's personalize your content